Australia markets closed

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.27+0.82 (+18.43%)
At close: 04:00PM EDT
5.18 -0.09 (-1.71%)
Pre-market: 07:39AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.09B
Enterprise value 1.52B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.92
Price/book (mrq)56.59
Enterprise value/revenue 4.60
Enterprise value/EBITDA -13.10

Trading information

Stock price history

Beta (5Y monthly) 1.93
52-week change 3-38.58%
S&P500 52-week change 325.77%
52-week high 38.96
52-week low 34.03
50-day moving average 34.93
200-day moving average 35.93

Share statistics

Avg vol (3-month) 33.38M
Avg vol (10-day) 33.9M
Shares outstanding 5206.33M
Implied shares outstanding 6206.33M
Float 8191.4M
% held by insiders 11.04%
% held by institutions 187.50%
Shares short (15 Apr 2024) 434.39M
Short ratio (15 Apr 2024) 49.91
Short % of float (15 Apr 2024) 416.80%
Short % of shares outstanding (15 Apr 2024) 416.67%
Shares short (prior month 15 Mar 2024) 430.55M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -58.69%
Operating margin (ttm)-15.62%

Management effectiveness

Return on assets (ttm)N/A
Return on equity (ttm)N/A

Income statement

Revenue (ttm)355.4M
Revenue per share (ttm)1.81
Quarterly revenue growth (yoy)34.90%
Gross profit (ttm)N/A
EBITDA -81.68M
Net income avi to common (ttm)-208.58M
Diluted EPS (ttm)-1.07
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)388.99M
Total cash per share (mrq)1.88
Total debt (mrq)848.71M
Total debt/equity (mrq)N/A
Current ratio (mrq)N/A
Book value per share (mrq)-2.21

Cash flow statement

Operating cash flow (ttm)N/A
Levered free cash flow (ttm)N/A